Company / Operating Cash Flow
Stoke Therapeutics, Inc. Operating Cash Flow History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
$45.6M
FY2025
5-year range
-$81.1M / $45.6M
FY2021-FY2025
Trend
+156.2%
vs FY2024
Sector context
#64 of 216
Health Care
What the data says
At $46M, Stoke Therapeutics, Inc.'s operating cash flow ranks #64 of 216 in the Health Care sector. Improved from -$32M to $46M over the past 2 years.
Based on SEC 10-K filings.
$46M in FY2025.
Improved from -$32M to $46M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#64 of 216 in Health CareTop 30% of 216This company $45.6M Sector average $658.7M
▼
-93.1% below sector average
Key checks
Key Insights
- In FY2025, operating cash flow increased 156.2% year-over-year.
- Ranks #64 out of 216 companies in the Health Care sector.
- Lowest operating cash flow in the period was in FY2024.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $45.6M | +156.2% |
| FY2024 | -$81.1M | -154.4% |
| FY2023 | -$31.9M | +52.4% |
| FY2022 | -$66.9M | +0.0% |
| FY2021 | -$66.9M | -58.5% |
| FY2020 | -$42.2M | -36.0% |
| FY2019 | -$31.1M | -183.2% |
| FY2018 | -$11.0M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026